Ingevity Corporation (NYSE:NGVT – Get Free Report) CEO David Li sold 5,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $75.73, for a total transaction of $378,650.00. Following the completion of the sale, the chief executive officer owned 125,636 shares in the company, valued at $9,514,414.28. This represents a 3.83% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ingevity Trading Down 3.6%
Shares of Ingevity stock opened at $71.33 on Thursday. The stock has a market capitalization of $2.45 billion, a P/E ratio of 48.53 and a beta of 1.16. The company has a quick ratio of 1.15, a current ratio of 1.61 and a debt-to-equity ratio of 22.52. The company has a 50-day simple moving average of $73.91 and a 200 day simple moving average of $71.82. Ingevity Corporation has a 12-month low of $45.85 and a 12-month high of $79.29.
Ingevity (NYSE:NGVT – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 EPS for the quarter, beating analysts’ consensus estimates of $1.33 by $0.41. The firm had revenue of $314.10 million for the quarter, compared to analyst estimates of $312.20 million. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. Research analysts expect that Ingevity Corporation will post 5.4 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Get Our Latest Stock Report on Ingevity
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Los Angeles Capital Management LLC increased its position in Ingevity by 94.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 30,877 shares of the company’s stock worth $1,827,000 after purchasing an additional 14,975 shares during the period. Pacer Advisors Inc. acquired a new position in Ingevity during the 4th quarter valued at about $9,660,000. Principal Financial Group Inc. boosted its stake in shares of Ingevity by 4.0% in the 1st quarter. Principal Financial Group Inc. now owns 678,037 shares of the company’s stock valued at $48,297,000 after purchasing an additional 25,800 shares during the last quarter. Bessemer Group Inc. grew its position in shares of Ingevity by 465.9% during the 1st quarter. Bessemer Group Inc. now owns 314,739 shares of the company’s stock worth $22,419,000 after buying an additional 259,124 shares during the period. Finally, Illinois Municipal Retirement Fund acquired a new stake in shares of Ingevity during the 1st quarter worth approximately $1,465,000. Institutional investors and hedge funds own 91.59% of the company’s stock.
About Ingevity
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Featured Articles
- Five stocks we like better than Ingevity
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
